Liver fibrosis with persistently normal alanine transaminase levels exhibits a distinct treatment response in MASLD. Journal Abstract - Guideline Central

Liver fibrosis with persistently normal alanine transaminase levels exhibits a distinct treatment response in MASLD.

Published: 2025 Oct 09

Authors

, , , , , , ,

Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD) presents considerable variability in disease progression and treatment outcomes. We aimed to determine whether specific patterns of liver inflammatory flares are correlated with distinct treatment responses.

Keywords: FIBROSIS, HEPATITIS, LIVER METABOLISM, OBESITY

Source

BMJ open gastroenterology

Publication Type

Journal Article

Language

English

PubMed ID

41067788

MeSH terms

You rely on Guideline Central for transparency

Guideline Central and select third party use “cookies” on this website to enhance the user experience.

This technology helps us gather statistical and analytical information to optimize the relevant content for you.

The user also has the option to opt-out which may have an effect on the browsing experience.